Corrigendum to ‘Three months extended-release microspheres prepared by multi-microchannel microfluidics in beagle dog models’. [Int. J. Pharm. 608 (2021) 121039]

Abstract

The authors regret that the following text must be corrected since Fig. 3c, 3d, 4, 5d, and 5e were processed from the raw data for one-month dog PK study published in the earlier article. The authors would like to apologise for any inconvenience caused. The corrected legends for Figure 3, 4, and 5 are as below with the reference: Figure 3. (a) Plasma drug concentration-time profiles after the administration of microspheres based on the ratio of 7502A:API (4:1) and 5002A:API (4:1), (b) cumulative plasma drug concentration-time profiles based on the ratio of 7502A:API (4:1) and 5002A:API (4:1), (c) plasma drug concentration-time profiles based on the ratio of 7502A:API (4:1), 7502A:API (2:1), and 7502A:API (2:1) with 20 mg API (71.4% of dose) (black line), and (d) cumulative plasma drug concentration-time profiles based on the ratio of 7502A:API (4:1), 7502A:API (2:1), and 7502A:API (2:1) with 20 mg API (71.4% of dose) (black line). Each point represents the mean ± SD (n = 9). Red and blue lines in (c) and (d) were generated using the same raw data reported earlier (Kang et al., 2021). Figure 4. (a) Plasma drug concentration-time profiles after the administration of microspheres based on 2.8 mg drug (10% of dose), 5.6 mg drug (20% of dose), 11.2 mg drug (40% of dose), 16.8 mg drug (60% of dose), and 28 mg drug (100% of dose), and (b) cumulative plasma drug concentration-time profiles after the administration of the microspheres. Each point represents the mean ± SD (n = 5). Results were generated using the same raw data reported earlier (Kang et al., 2021). Figure 5. (d) Plasma concentration of 1 mg Propecia® tablet, and (e) 1 month simulation study of the plasma concentration of 1 mg Propecia® tablet administered daily. Each point represents the mean ± SD (n = 5). (d) and (e) were generated using the raw data reported earlier (Kang et al., 2021). ReferenceKang, D.W., Ryu, C.H., Kim, J.H., Choi, G.-W., Kim, S., Chon, C.H., Cho, H.-Y., 2021. Pharmacokinetic-pharmacodynamic modeling approach for dose prediction of the optimal long-acting injectable formulation of finasteride. Int. J. Pharm. 601, 120527. © 2021 Elsevier B.V.